Pharmaceutical UK-based Mundipharma has announced the positive outcome of the European Decentralised Procedure (DCP) for flutiform k-haler, a novel asthma treatment for adults and adolescents that contains the same combination of fluticasone propionate and formoterol fumarate (50/5μg and 125/5μg strengths) as the company’s existing asthma maintenance combination, flutiform pMDI (pressurised metered dose inhaler). 5 October 2017